Dublin, Feb. 08, 2019 (GLOBE NEWSWIRE) -- The "Liquid Biopsies 2019" conference has been added to ResearchAndMarkets.com's offering.

Liquid Biopsies 2019 focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers. There is much interest in the potential of ctDNA for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this track bring together the most up-to-date information and current state-of-the-field. The conference further explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for early disease screening, patient monitoring, and minimal residual disease detection. This conference is held concurrently with the Circulating Biomarkers 2019 Conference enabling delegates full access to the scientific presentations at both conferences, co-located exhibit hall, and extensive networking opportunities.

Agenda:

DAY 1 - WEDNESDAY, 27 MARCH 2019 08:00 - Conference Registration, Materials Pick-Up, Morning Coffee and Breakfast Pastries 08:45 - Conference Chair

  • Conference Co-Chaiperson Opening Remarks and Welcome to Delegates
  • Paul Robbins, Professor, Department of Biochemistry, Molecular Biology, and Biophysics, and the Institute on the Biology of Aging and Metabolism, University of Minnesota Medical School, United States of America
  • Session Title: Conference Plenary Session -- Emerging Themes in Circulating Biomarkers and Liquid Biopsies
  • Plenary Session Chairperson: Lucia R. Languino, Ph.D., Professor of Cancer Biology, Thomas Jefferson University

09:00 - Keynote Presentation

  • Mt-SEA Pipeline: High Throughput Flow Cytometric Analysis of Exosomes in Clinical Biofluids
  • Jennifer Jones, Staff Clinician, Molecular Immunogenetics & Vaccine Research Section, National Cancer Institute (NCI), United States of America

09:30 - Keynote Presentation

  • Disease-Specific Vascular Markers for Cancer, Atherosclerosis and Brain Diseases
  • Erkki Ruoslahti, Distinguished Professor and Former President, Sanford Burnham Prebys Medical Discovery Institute, United States of America

10:00 - Coffee Break and Networking in the Exhibit Hall 10:45 - Keynote Presentation Precision Medicine Using Liquid Biopsies: A New Paradigm for Managing Cancer Diseases Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology, United States of America 11:15 - Conference Chair

  • Exosomes: Novel Opportunities for the Diagnosis and Therapy of Cancer
  • Lucia Languino, Professor of Cancer Biology, Thomas Jefferson University, United States of America

11:45 - Keynote Presentation

  • Tumor-derived Exosomes Contribute to a Pro-inflammatory Tumor Microenvironment through the Stimulation of Chemokines and Cytokines in Mesenchymal Stromal Cells and Macrophages
  • Yves A. DeClerck, Professor of Pediatrics and Biochemistry & Molecular Medicine, Children's Hospital Los Angeles, University of Southern California, United States of America

12:15 - Networking Lunch in the Exhibit Hall and Poster Viewing

  • Session Title: Circulating Cell-Free DNA (cfDNA) -- A Valuable Circulating Biomarker for Liquid Biopsy Development

14:00 - Ultrasensitive Detection of Cancer Using cfDNA Methylation Sequencing

  • Jasmine Zhou, Professor, University of California-Los Angeles, United States of America

14:30 - Low Coverage, Genome-Wide Sequencing of Cell-Free DNA Enables the Monitoring of Response to Immunotherapy in Cancer Patients

  • Taylor Jensen, Director, Research and Development, Sequenom (a LabCorp Company), United States of America

15:00 - Ultra-Sensitive Mutational Analysis in Cell-Free DNA by Digital PCR and NGS Technologies

  • Rachel Tam, Senior Scientific Researcher, Oncology Biomarker Development, Genentech, United States of America

15:30 - Afternoon Coffee Break in the Exhibit Hall 16:00 - Early Cancer Detection in Plasma by Methylation Haplotyping

  • Kun Zhang, Professor, Department of Bioengineering, University of California San Diego, United States of America

16:30 - Monitoring Recurrence With Personalized ctDNA Assays

  • Bernhard Zimmermann, Vice President of Research and Development, Natera, United States of America

17:00 - cfDNA Analysis in ALK-positive NSCLC Patients and Potential Clinical Utility

  • Jean-Franois Martini, Sr. Director, Translational Oncology, Immuno-Oncology, Early Development, Pfizer, United States of America

18:00 - Networking Reception with Beer and Wine in the Exhibit Hall 19:00 - Close of Day 1 of the Conference. DAY 2 - THURSDAY, 28 MARCH 2019 08:30 - Morning Coffee and Breakfast Pastries Served in the Exhibit Hall

  • Session Title: Liquid Biopsy Development for Cancer

09:00 - Keynote Presentation

  • Biological Functions and Methods of Detection of Large Oncosomes in Cancer
  • Dolores Di Vizio, Professor, Cedars Sinai Medical Center, United States of America

09:30 - Circulating Tumor DNA Analyses in Lung Cancer

  • Hatim Husain, Assistant Professor of Medicine, University of California San Diego, United States of America

10:00 - Keynote Presentation

  • Liquid Biopsy in MBC: Real-time Evaluation of Tumor Heterogeneity and Molecular Evolution in Clinical Management
  • Massimo Cristofanilli, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, United States of America

10:30 - Coffee Break and Networking in the Exhibit Hall 11:00 - Circulating Biomarkers: The New Nanotube-CTC-Microarray Chip for Clinical Impact

  • Balaji Panchapakesan, Professor, Department of Mechanical Engineering, Worcester Polytechnic Institute (WPI), United States of America

1 1:30 - Keynote Presentation

  • Customized Circulating Tumor DNA Platform for Cancer Research
  • Cheng-Ho Jimmy Lin, Chief Scientific Officer, Oncology, Natera, United States of America

12:00 - Networking Lunch in the Exhibit Hall and Poster Viewing 13:00 - Quantitative Detection of Gene Rearrangements Using Circulating Tumor Cells Purified by a Covalent Chemistry-Enabled Platform

  • Yazhen Zhu, Assistant Project Scientist, David Geffen School of Medicine at UCLA, United States of America

13:30 - Keynote Presentation

  • Multi-Omic Liquid Biopsy Platform
  • Sam Hanash, Director, McCombs Institute for Cancer Detection and Treatment, University of Texas MD Anderson Cancer Center, United States of America
  • Multiple technologies are currently being explored for liquid biopsy applications beyond genomics, including proteomics, metabolomics, immunomics and extra-cellular vesicles. The individual and combined contributions of these approaches will be presented.

14:00 - Keynote Presentation

  • New Molecular Approaches of Blood Biopsy To Monitor Melanoma Patients Progression During Treatment
  • David Hoon, Professor, Director Department of Translational Molecular Medicine, John Wayne Cancer Institute, United States of America
  • Will present new platforms to assess blood biopsy in melanoma patients receiving therapy. New approaches in assessing the utility of CTC and cfNA detection.

14:30 - Title to be Confirmed.

  • John Palma, Chief Medical Officer, Roche Sequencing Solutions, United States of America

15:00 - Characterizing Cell-Free Circulating RNA - A Dream or a Reality?

  • Kai Wang, Principal Scientist, Institute for Systems Biology, United States of America
  • Circulating RNA, especially RNA encapsulated in lipid vesicles, has gained significant interest due to their biological function and possible clinical applications. Despite the potential utilities, it is still a challenge to accurately profile the circulating RNA. Some of the challenges and technology improvements on characterizing cell-free circulating RNA will be addressed.

15:30 - Afternoon Coffee Break in the Exhibit Hall 16:00 - Keynote Presentation

  • Title to be Confirmed.
  • Lydia Sohn, Professor, Department of Mechanical Engineering, University of California, Berkeley, United States of America

16:30 - Circulating Tumor DNA Methylation Markers for Diagnosis and Prognosis of Hepatocellular Carcinoma

  • Kang Zhang, Founding Director, Institute for Genomic Medicine, University of California-San Diego, United States of America
  • We identified an HCC-specific methylation marker by comparing HCC tissue and normal blood leukocytes and showed that methylation profiles of HCC tumor DNA and matched plasma ctDNA are highly correlated. We constructed a diagnostic prediction model with high diagnostic specificity and sensitivity and was highly correlated with tumor burden, treatment response, and stage. Additionally, we constructed a prognostic prediction model that effectively predicted prognosis and survival.

17:30 - Industry Panel Discussion Focusing on Circulating Biomarkers & Liquid Biopsy 18:15 - Close of Day 2 of the Conference Track DAY 3 - FRIDAY, 29 MARCH 2019 08:30 - Morning Coffee and Breakfast Pastries Served in the Exhibit Hall

  • Session Title: Late-Breaking Session

09:00 - Highly Sensitive Direct Quantification of cfmiRNAs for Biomarker Profiling by Next Generation Sequencing (NGS)

  • Sergio Barberan-Soler, Director of Sequencing Technologies, Somagenics, Inc, United States of America
  • Inefficient and inaccurate profiling of microRNAs from biofluids has hindered their usage as biomarkers. We have developed accurate library preparation technologies to profile microRNAs directly from biofluid samples.

09:30 - Applying ctDNA and Other Liquid Biopsy Technologies for Oncology Translational and Clinical Research

  • Brian Dougherty, Executive Director, Translational Genomics, Oncology IMED, AstraZeneca R&D, United States of America
  • Opportunities and challenges in ctDNA testing for mutational profiling, patient selection, and patient monitoring
  • Orthogonal bench-marking study of commercial ctDNA assays
  • One finding: in current testing, most tumor-plasma discordance is due to assay technical performance, not tumor heterogeneity or clonal hematopoesis
  • Landscape of the exosomal transcriptome and some potential implications for use for cancer patient testing
  • Single cell DNA and RNA technologies
  • Testing of patient samples from hematological cancers by single cell sequencing

10:00 - BloodPAC: Establishing Standards to Accelerate Development and Approval of Liquid Biopsy Technology

  • Lauren Leiman, Executive Director, Blood Profiling Atlas in Cancer (BloodPAC), United States of America

10:30 - Toward Perfect Detection of Un-amplified Biomarkers with Single-Molecule Kinetic Fingerprinting

  • Alexander Johnson-Buck, Research Assistant Professor, University of Michigan, United States of America

11:00 - Keynote Presentation

  • Liquid Biopsies - A New Tool in the Personalized Cancer Therapy Toolbox
  • Filip Janku, Associate Professor, Center Medical Director, Clinical and Translational Research Center, The University of Texas MD Anderson Cancer Center, United States of America

For more information about this conference visit https://www.researchandmarkets.com/research/p...psies?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: In Vitro Diagnostics